NZ711958A - Compositions and methods of using islet neogenesis peptides and analogs thereof - Google Patents

Compositions and methods of using islet neogenesis peptides and analogs thereof

Info

Publication number
NZ711958A
NZ711958A NZ711958A NZ71195814A NZ711958A NZ 711958 A NZ711958 A NZ 711958A NZ 711958 A NZ711958 A NZ 711958A NZ 71195814 A NZ71195814 A NZ 71195814A NZ 711958 A NZ711958 A NZ 711958A
Authority
NZ
New Zealand
Prior art keywords
analogs
peptides
methods
compositions
islet neogenesis
Prior art date
Application number
NZ711958A
Other languages
English (en)
Inventor
Liping Liu
Ru Bai
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Priority to NZ751589A priority Critical patent/NZ751589A/en
Priority to NZ751591A priority patent/NZ751591A/en
Publication of NZ711958A publication Critical patent/NZ711958A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0613—Cells from endocrine organs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
NZ711958A 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof NZ711958A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ751589A NZ751589A (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof
NZ751591A NZ751591A (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/072771 WO2014139182A1 (en) 2013-03-15 2013-03-15 Compositions and methods of using islet neogenesis peptides and analogs thereof
PCT/CN2014/073483 WO2014139472A1 (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof

Publications (1)

Publication Number Publication Date
NZ711958A true NZ711958A (en) 2020-07-31

Family

ID=51535856

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ711958A NZ711958A (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof

Country Status (15)

Country Link
US (7) US20160039877A1 (enExample)
EP (2) EP2970385B1 (enExample)
JP (2) JP6674258B2 (enExample)
KR (1) KR102244349B1 (enExample)
CN (9) CN104650212A (enExample)
AU (3) AU2014231444B2 (enExample)
BR (1) BR112015022469A2 (enExample)
CA (1) CA2906240C (enExample)
ES (1) ES2703110T3 (enExample)
IL (1) IL241383B (enExample)
MX (2) MX378245B (enExample)
NZ (1) NZ711958A (enExample)
RU (1) RU2685958C2 (enExample)
SG (1) SG11201507404RA (enExample)
WO (2) WO2014139182A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4560952B2 (ja) * 1999-12-03 2010-10-13 株式会社セガ ゲーム装置及びゲームシステム
CA2901404A1 (en) * 2013-02-15 2014-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Modified ingap peptides for treating diabetes
AU2016392719A1 (en) 2016-02-10 2018-08-02 Pfizer Inc. Therapeutic nanoparticles having EGFR ligands and methods of making and using same
EP3426678B1 (en) * 2016-03-10 2025-07-02 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugates of islet neogenesis peptides and analogs, and methods thereof
CN105837677B (zh) * 2016-04-15 2020-12-25 上海交通大学 一种经改性的蛋白及其制备方法和应用
CN108616978B (zh) * 2016-12-14 2022-04-15 中兴通讯股份有限公司 一种网络功能实体进行无状态处理的方法及装置
KR102006890B1 (ko) * 2016-12-27 2019-08-05 한양대학교 산학협력단 췌장 소도 세포 표적 펩타이드 및 이의 용도
CN110958885B (zh) * 2017-05-11 2024-03-12 深圳君圣泰生物技术有限公司 多肽化合物在治疗急性胰腺炎中的应用
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies
JP7395517B2 (ja) * 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
CN114702550B (zh) * 2018-09-18 2023-09-12 广州领晟医疗科技有限公司 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
KR101995768B1 (ko) 2019-03-13 2019-07-03 (주)엔솔바이오사이언스 신규 펩타이드 및 그 용도
US20230193316A1 (en) * 2020-05-01 2023-06-22 The Broad Institute, Inc. Engineered central nervous system compositions
US12668814B2 (en) 2020-07-22 2026-06-30 The Broad Institute, Inc. Engineered muscle targeting compositions
CN112759640B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胃泌素受体双重激动剂及其应用
US20250064888A1 (en) * 2022-01-25 2025-02-27 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating cytokine storm
CN120659618A (zh) * 2023-02-16 2025-09-16 深圳君圣泰生物技术有限公司 用于治疗肝病的组合物和方法
CN118772232B (zh) * 2023-04-10 2025-08-22 湖南中晟全肽生物科技股份有限公司 蛙皮素类多肽化合物及其用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
FR2700011B1 (fr) 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5804421A (en) 1996-10-30 1998-09-08 Eastern Virginia Medical School Of The Medical College Fo Hampton Roads High level of expression of ingap in bacterial and euraryotic cells
US5935813A (en) 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020052308A1 (en) 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US20040018623A1 (en) 1999-10-29 2004-01-29 Lawrence Rosenberg Medium for preparing dedifferentiated cells
US20020009730A1 (en) 1999-11-17 2002-01-24 Alex Chenchik Human stress array
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DE10056802B4 (de) 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
DE60138764D1 (de) 2000-12-13 2009-07-02 Anaphore Inc Methode zur identifikation und isolation von peptide die andere moleküle binden aus kombinatorische proteinbibliotheken mit einer c-typ lectin-ähnlichen domäne als gerüststruktur
US20040018970A1 (en) 2000-12-19 2004-01-29 Shimkets Richard A. Novel nucleic acids and polypeptides and methods of use thereof
WO2002059315A2 (en) 2000-12-19 2002-08-01 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
US6986994B2 (en) 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays
US20040158036A1 (en) 2001-03-01 2004-08-12 Lawrence Rosenberg Neuritogenic compound and uses thereof
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US20040132644A1 (en) 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7662768B2 (en) 2002-01-11 2010-02-16 Mcgill University Transdifferentiation of pancreatic acinar cells
US7166439B2 (en) 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20030212000A1 (en) 2002-05-09 2003-11-13 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
JP2005532077A (ja) 2002-07-10 2005-10-27 オンコセラピー・サイエンス株式会社 腸型胃腫瘍の診断法
JP2004065120A (ja) 2002-08-07 2004-03-04 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患の疾患マーカー及びその利用
ATE452650T1 (de) 2002-08-30 2010-01-15 Biorexis Pharmaceutical Corp Transferrin-fusionsproteinbibliotheken
US20060009516A1 (en) 2002-10-24 2006-01-12 Mcgill University Use of ingap for reversing diabetes
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US7510708B2 (en) 2003-04-14 2009-03-31 Washington University Disruption of the REG pathway
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
WO2005113812A2 (en) 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20050277593A1 (en) 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
BRPI0511069A (pt) 2004-06-04 2007-11-27 Wyeth Corp inibidores de proteìnas regiii como terapêutica para asma
KR100639677B1 (ko) 2004-11-08 2006-10-30 삼성전자주식회사 위상 및 지연 동기 루프와 이를 구비한 반도체 메모리 장치
KR100664586B1 (ko) 2004-12-22 2007-01-04 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP2008545712A (ja) * 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
WO2007056511A2 (en) 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
US20080039393A1 (en) 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
WO2007071437A2 (en) 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
WO2008011518A2 (en) 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
KR20060089873A (ko) 2006-07-25 2006-08-09 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2082343A2 (en) 2006-11-02 2009-07-29 Genizon Biosciences Inc. Genemap of the human genes associated with asthma disease
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
FR2910311B1 (fr) 2006-12-20 2009-02-13 Oreal Composition comprenant un compose silicone et un organosilane particulier
US7923014B2 (en) 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
JP2010522762A (ja) * 2007-03-26 2010-07-08 サルトリア・フアーマシユーテイカルズ・エル・エル・シー 糖尿病の治療のための方法及びプロブコール誘導体の組成物
US20080280985A1 (en) 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
PT2193142E (pt) * 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
WO2009049222A1 (en) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
US20100004213A1 (en) 2007-11-29 2010-01-07 Abbas Alexander R Gene expression markers for inflammatory bowel disease
AU2008334095A1 (en) 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
US20100331248A1 (en) 2008-01-31 2010-12-30 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide
AU2009226246A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP2010085375A (ja) 2008-10-02 2010-04-15 Nationa Hospital Organization 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US8012928B2 (en) 2008-12-19 2011-09-06 The Research Foundation Of State University Of New York Truncated PAP2 and methods of making and using same
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
ES2356217B1 (es) 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
EP2486132A1 (en) 2009-10-09 2012-08-15 Anaphore, Inc. Combinatorial libraries based on c-type lectin domain
US20110086770A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
ES2374370B1 (es) 2010-08-04 2013-01-08 Universidad De Salamanca Método para la detección de daño renal.
CN102827253B (zh) * 2011-06-17 2017-07-21 上海市第一人民医院 一种抑制炎症反应的小分子多肽及其应用
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CA2901404A1 (en) * 2013-02-15 2014-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Modified ingap peptides for treating diabetes

Also Published As

Publication number Publication date
JP2020062028A (ja) 2020-04-23
AU2020280993A1 (en) 2021-01-07
SG11201507404RA (en) 2015-10-29
MX2019009886A (es) 2019-10-22
EP2970385B1 (en) 2018-10-03
CN104045703A (zh) 2014-09-17
IL241383B (en) 2021-03-25
AU2014231444A1 (en) 2015-10-01
EP3473642A2 (en) 2019-04-24
CN104045698A (zh) 2014-09-17
JP2016512205A (ja) 2016-04-25
AU2018241212A1 (en) 2018-11-29
KR20160012992A (ko) 2016-02-03
RU2015143655A3 (enExample) 2018-02-28
CN104045698B (zh) 2019-04-16
MX378245B (es) 2025-03-10
KR102244349B1 (ko) 2021-04-23
AU2014231444B2 (en) 2018-07-19
CN104650212A (zh) 2015-05-27
US20180009861A1 (en) 2018-01-11
US20160039877A1 (en) 2016-02-11
BR112015022469A2 (pt) 2017-07-18
WO2014139472A1 (en) 2014-09-18
US10899815B2 (en) 2021-01-26
JP6674258B2 (ja) 2020-04-01
US9738695B2 (en) 2017-08-22
ES2703110T3 (es) 2019-03-07
CN104045703B (zh) 2021-04-06
AU2018241212B2 (en) 2020-09-17
EP2970385A4 (en) 2016-12-07
CN104592380A (zh) 2015-05-06
US20190023755A1 (en) 2019-01-24
CA2906240C (en) 2022-10-18
AU2020280993B2 (en) 2022-04-21
CA2906240A1 (en) 2014-09-18
CN104045701A (zh) 2014-09-17
JP7075918B2 (ja) 2022-05-26
US9388215B2 (en) 2016-07-12
EP2970385A1 (en) 2016-01-20
CN104045699A (zh) 2014-09-17
CN104045700A (zh) 2014-09-17
US20220348618A1 (en) 2022-11-03
RU2015143655A (ru) 2017-04-26
WO2014139182A1 (en) 2014-09-18
IL241383A0 (en) 2015-11-30
US20200347106A1 (en) 2020-11-05
RU2685958C2 (ru) 2019-04-23
CN104045702A (zh) 2014-09-17
MX2015012038A (es) 2016-06-02
CN104650211A (zh) 2015-05-27
EP3473642A3 (en) 2019-07-10
EP3473642B1 (en) 2022-04-13
US20170002049A1 (en) 2017-01-05
US20150203538A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
MX2019009886A (es) Composiciones y metodos para utilizar peptidos de neogenesis de islote y analogos de los mismos.
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
PH12020550450A1 (en) Certain chemical entities, compositions and methods
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
SG10201809428UA (en) Insulin receptor partial agonists
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SG10201902872YA (en) Ex vivo proliferation of epithelial cells
PH12019502646A1 (en) Pyrazole magl inhibitors
EP4516319A3 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX393988B (es) Variantes de interferon a2b.
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
EP4667565A3 (en) Methods and compositions for the treatment of fabry disease
MX2018011162A (es) Metodos de purificacion de colageno 7.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
PH12019501683A1 (en) Rorgamma modulators and uses thereof
MX367858B (es) Péptidos de conotoxina, composiciones farmacéuticas y usos de los mismos.
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY HENRY HUGHES IP LIMITED

Effective date: 20210216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2023 BY HENRY HUGHES IP LIMITED

Effective date: 20220208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2024 BY HENRY HUGHES IP LIMITED

Effective date: 20230131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2025 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20240304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2026 BY DENNEMEYER AND CO. SARL

Effective date: 20250304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2027 BY DENNEMEYER + CO. SARL

Effective date: 20260302